Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

NCT00300885 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00300885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00300885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2006
Completion date
February 28, 2009
Enrollment
926 (actual)
Sites
202

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung